


CLAIMS

1. Use of a glutaminase inhibitor in the manufacture of a medicament for treating cancer, wherein the medicament is for conjoint administration with cabozantinib; and the glutaminase inhibitor is a compound of formula II:



(II), or a pharmaceutically acceptable salt

thereof.

2. The use of claim 1, wherein the cancer is selected from brain tumor, breast cancer, hepatocellular cancer, lung cancer including non-small cell lung cancer and small cell lung cancer, melanoma, ovarian cancer, prostate cancer, and renal cell cancer.


3. The use of claim 2, wherein the cancer is non-small cell lung cancer.

4. The use of claim 2, wherein the cancer is renal cell cancer.

5. The use of any one of claims 2-4, wherein the cancer is resistant to cabozantinib.

6. The use of claim 1, wherein the cancer is renal cell carcinoma, breast cancer, brain tumor, hepatocellular cancer, non-small cell lung cancer, melanoma, ovarian cancer, or prostate cancer.


7. A pharmaceutical composition comprising a glutaminase inhibitor and cabozantinib; wherein the glutaminase inhibitor is a compound of formula II:



(II), or a pharmaceutically acceptable salt

thereof.


8. A pharmaceutical kit comprising:
 cabozantinib;
 a glutaminase inhibitor; and
 optionally directions on how to administer cabozantinib and the glutaminase inhibitor;
 wherein the glutaminase inhibitor is a compound of formula II:



(II), or a pharmaceutically acceptable salt

thereof.

9. Use of a glutaminase inhibitor and cabozantinib in the manufacture of a medicament for treating cancer, wherein the glutaminase inhibitor is a compound of formula II:



(II), or a pharmaceutically acceptable salt

thereof.